Document is current
Any future updates will be listed below
-
Authors
Gao, Mingjun https://orcid.org/0000-0003-2789-713X
Hou, Yanhua https://orcid.org/0009-0008-2448-064X
Lu, Yutong https://orcid.org/0009-0003-3005-4480
Shi, Zhanhua https://orcid.org/0009-0001-7208-8158
-
Clinical Trials BETA
Clinical trials referenced in this document:
chictr2500098887 at Chinese Clinical Trial RegistryDocuments that mention this clinical trial
Efficacy and Safety of 0.01% Atropine Eye Drops and Novel Lenslet-ARray-Integrated Spectacle Lenses for the Prevention of Myopia Progression Among Children with Premyopia: A Randomized Clinical Trial
https://doi.org/10.1007/s40123-025-01214-y
- License Information
-
More Information
Article History
Received: 17 June 2025
Accepted: 15 July 2025
First Online: 19 August 2025
Declarations
:
: Mingjun Gao, Yanhua Hou, Yutong Lu, Zhanhua Shi, and Qi Zhao have nothing to disclose.
: The study followed the principles of the Declaration of Helsinki and was approved by the institutional review board of The Second Hospital of Dalian Medical University (KY2024-206-01). The trial was registered in the Chinese Clinical Trial Registry () with the registration number ChiCTR2500098887 due to unavoidable post-pandemic institutional review backlog and administrative complexities beyond control. Despite retrospective registration, the pre-specified statistical analysis plan was adhered to, and there were no changes in the protocol and methods after trial commencement. All outcomes registered match those reported. The trial original protocol is available in the Supplementary Material. For subjects under 8 years of age, we obtained informed written consent from their legal guardians. For subjects aged ≥ 8 years, we obtained the informed consent of the subjects themselves and their legal guardians.
